Business Context and Reporting Period
This summary covers the Form 10-Q filed by AmerisourceBergen Corporation (Note: The company name in the metadata "Cencora" is incorrect for this 2007 filing; the registrant is AmerisourceBergen) for the quarterly period ended March 31, 2007. The company operates as a pharmaceutical services provider, organized into two reportable segments: Pharmaceutical Distribution (comprising AmerisourceBergen Drug Corporation, Specialty Group, and Packaging Group) and PharMerica (Long-Term Care and workers' compensation services).
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2007 | Six Months Ended Mar 31, 2007 |
|---|---|---|
| Operating Revenue | $15.28 billion | $30.98 billion |
| Total Revenue (incl. bulk deliveries) | $16.51 billion | $33.24 billion |
| Gross Profit | $606.4 million | $1,201.1 million |
| Operating Income | $220.9 million | $429.8 million |
| Net Income | $129.5 million | $251.7 million |
| Diluted EPS | $0.68 | $1.30 |
| Cash from Operating Activities | N/A (Quarterly not provided) | $710.8 million |
| Total Debt (Outstanding) | $1.20 billion | $1.20 billion |
| Cash & Short-term Investments | $1.61 billion | $1.61 billion |
Margins (Six Months Ended Mar 31, 2007): Gross profit margin was 3.88% of operating revenue; Operating income margin was 1.39%.
Material Changes vs. Prior Period
- Revenue Growth: Operating revenue increased 9% for the quarter and 12% for the six-month period compared to the prior year. Growth was driven by the Pharmaceutical Distribution segment, specifically the Specialty Group (34% growth) and AmerisourceBergen Drug Corporation (5% growth).
- Profitability: Operating income rose 12% for the quarter and 18% for the six-month period. Net income increased 1% for the quarter and 11% for the six-month period.
- Antitrust Gains: Gains from antitrust litigation settlements decreased significantly. The company recognized $3.6 million in gains for the six months ended March 31, 2007, compared to $27.4 million in the prior-year period. These gains are recorded as a reduction to cost of goods sold.
- Interest Expense: Net interest expense increased 30% for the six-month period to $18.0 million, primarily due to higher average borrowings.
- Share Count: Weighted average shares outstanding decreased by 8% year-over-year due to aggressive share repurchases, contributing to a 21% increase in diluted EPS despite only an 11% increase in net income.
Guidance, Outlook, and Risks
- Revenue Outlook: Management expects operating revenue growth for the full fiscal year 2007 to range between 9% and 11%. Growth is expected to moderate in the second half of the year compared to the first half.
- Cash Flow Outlook: The company expects cash provided from operating activities for fiscal 2007 to be between $675 million and $775 million.
- Acquisitions:
- Bellco Health: Agreed to acquire Bellco for approximately $235 million. However, the acquisition faces uncertainty as the DEA suspended Bellco's license to distribute controlled substances on May 3, 2007, citing concerns over sales to internet pharmacies.
- Xcenda: Acquired in April 2007 for $25.0 million to enhance specialty services.
- Divestiture: The company is proceeding with a transaction to combine its PharMerica Long-Term Care business with Kindred Healthcare's pharmacy business into a new independent company (PharMerica Corporation), expected to close in the second quarter of 2007.
- Regulatory Risks:
- DEA Suspension: The company's own Orlando distribution center license was suspended by the DEA in April 2007 regarding diversion of controlled substances, though partially lifted shortly after.
- Reimbursement: Risks associated with the Deficit Reduction Act (DRA) and potential reductions in Medicaid reimbursement rates for generic drugs. Additionally, FDA black box warnings on anemia drugs may reduce utilization and reimbursement.
- Legal Contingencies: Significant pending litigation includes the "Bergen Brunswig Matter" (a former executive lawsuit with a $19.4 million judgment pending appeal) and the "Bridge Medical Matter" (dispute over contingent purchase price payments).
Investor Verification Checklist
- Bellco Acquisition Status: Verify the impact of the DEA suspension on the pending $235 million Bellco Health acquisition and whether the deal will close as planned.
- DEA Compliance: Monitor the resolution of the DEA suspension of the company's Orlando distribution center and any associated fines or operational restrictions.
- Antitrust Settlements: Assess the sustainability of earnings given the sharp decline in antitrust litigation gains ($27.4M prior year vs. $3.6M current year).
- PharMerica Spin-off: Confirm the timeline and financial terms of the PharMerica Long-Term Care divestiture/combination with Kindred Healthcare.
- Reimbursement Policy Changes: Evaluate the potential financial impact of the Deficit Reduction Act (DRA) and CMS rule changes on the Long-Term Care segment's margins.
- Share Repurchase Program: Note that $386.6 million remained available under the share repurchase program as of March 31, 2007, with additional purchases made subsequent to the quarter.